ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0026

Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)

Nadine Honke1, Tim Appel1, Matthias Schneider2 and Georg Pongratz3, 1Department of Rheumatology, Hiller Research Center Rheumatology, University Hospital Düsseldorf, Germany (* contributed equally), Düsseldorf, Germany, 2Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, 3Polyclinic and Functional Area for Rheumatology & Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany

Meeting: ACR Convergence 2021

Keywords: Fibroblasts, Synovial, Interleukins, Metalloproteinase, Osteoarthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The milk protein αS1-Casein (CSN1S1) was described to be overexpressed in synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Recently we were able to show that αS1-Casein is capable of inducing the secretion of proinflammatory cytokines in human monocytic cells. Since synovial fibroblasts are known to regulate propagation of inflammation and contribute to cartilage and bone destruction in RA, our aim was to investigate whether αS1-Casein increases the pathogenic potential of RA and OA synovial fibroblasts (RASF and OASF).

Methods: Fibroblasts were isolated from synovial tissues obtained from patients diagnosed with RA and OA who underwent synovectomy due to total joint replacement. RASF and OASF were cultivated in the presence or absence of procaryotic recombinant human αS1-Casein and LPS. Polymyxin B (5µg/ml, Px5) was added to cultured cells to rule out any LPS-effects. After 24 hours fibroblast-derived IL-6, IL-8 and MMP-3 were measured in the supernatant by ELISA.

Results: ELISA analysis showed that synovial fibroblasts from RA and OA patients acquire a proinflammatory and destructive phenotype after treatment with αS1-Casein. This proinflammatory phenotype was induced by αS1- Casein in a concentration-dependent manner with elevated secretion of IL-6 (Ctrl. vs. αS1-Casein (500ng/ml); n=5-6, RA: p***=0.0001; OA: p**=0.0048), IL-8 (Ctrl. vs. αS1-Casein (500ng/ml); n=5, RA: p****< 0.0001; OA: p*=0.0179) and MMP3 (Ctrl. vs. αS1-Casein (500ng/ml); n=5-6, RA: p***=0.0007; OA: n.s.). LPS treatment alone increased the levels of IL-6 (Ctrl. vs. LPS 1ng/ml; n=5-6, RA: p*=0.0455, OA: n.s.; Ctrl. vs. LPS 10ng/ml; n=5-6, RA: p**=0.0039; OA: p**=0.0014), IL-8 (Ctrl. vs. LPS 1ng/ml; n=4-5, RA: p**=0.0037, OA: p**=0,0094; Ctrl. vs. LPS 10ng/ml; n=4-5, RA: p***=0.0005; OA: p***=0.0002) and MMP3 (Ctrl. vs. LPS 1ng/ml; n=5-6, RA: n.s; OA: p*=0.0433; Ctrl. vs. LPS 10ng/ml; n=5-6, RA: p*=0,0287; OA: p**=0.002). Addition of polymyxin B to αS1-Casein-treated fibroblasts did not significantly influence the secretion of the investigated factors (IL-6, IL-8, MMP3: αS1-Casein vs. αS1-Casein+Px5, n=4-6) while polymyxin B completely blunted the LPS-induced secretion (IL-6: LPS 10ng/ml vs. LPS 10ng/ml +Px5, n=5, RA: p*=0.0326; OA: p*=0.014; IL-8: LPS 10ng/ml vs. LPS 10ng/ml +Px5, n=5-6, RA: p**=0.0038; OA: p****< 0.0001; MMP3: LPS 10ng/ml vs. LPS 10ng/ml +Px5, n=6, RA: p*=0.0287; OA: n.s.). Furthermore, by using immunofluorescence histology of synovial tissue from RA and OA patients, we demonstrated that infiltration of casein-positive cells occurs mainly in RA and not OA patients.

Conclusion: In conclusion, our results suggest that casein-positive infiltrating cells are responsible for inducing a proinflammatory phenotype in RASF and augment their destructive capability. αS1-Casein might therefore be part of the pathomechanism of RA.


Disclosures: N. Honke, None; T. Appel, None; M. Schneider, GlaxoSmithKline, 2, 5, 6, UCB, 5, 6, AbbVie, 2, 5, Alexion, 2, AstraZeneca, 2, 6, Boehringer-Ingelheim, 2, Janssen-Cilag, 2, 6, Lilly, 2, 6, Novartis, 2, Pfizer, 2, 6, Roche, 2, Sanofi-Aventis, 2, Biogen, 6, BMS, 6, Celgene, 6, Chugai, 6; G. Pongratz, None.

To cite this abstract in AMA style:

Honke N, Appel T, Schneider M, Pongratz G. Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/synovial-fibroblasts-acquire-a-proinflammatory-and-destructive-phenotype-after-exposure-to-%ce%b1s1-casein-csn1s1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-fibroblasts-acquire-a-proinflammatory-and-destructive-phenotype-after-exposure-to-%ce%b1s1-casein-csn1s1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology